Elewaut D, Braun J, Anderson JK, et al. - Researchers tried to find out the incidence of inflammatory bowel disease (IBD) adverse events (AEs) across adalimumab trials. They examined IBD AE rates in 75 adalimumab clinical trials in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, pediatric enthesitis-related arthritis, uveitis, hidradenitis suppurativa, adult and pediatric psoriasis, psoriatic arthritis, non-psoriatic arthritis peripheral spondyloarthritis (pSpA), axial spondyloarthritis (axSpA), including non-radiographic axSpA and ankylosing spondylitis, were analyzed. A total of 24,114 patients were included, representing 36,508 patient-years (PY) of adalimumab exposure. In adalimumab clinical trials, it was noted that the rates of IBD AEs were generally low across the estimated diseases, including axSpA; all events occurred in adult individuals.